North America currently maintains the largest market share, accounting for over 41% of global revenue. This regional dominance stems from robust R&D spending and an established infrastructure for clinical trial services. Logistics and distribution remain the most significant segments, capturing 27.2% of the market as companies pivot toward direct-to-patient delivery models that require precise cold-chain management and real-time shipment monitoring.
Clinical Trial Supply Market Projected to Hit $8.95 Billion by 2031
The global market for clinical trial supplies is set to grow from $5.60 billion in 2026 to $8.95 billion by 2031, representing a compound annual growth rate of 8.9%. This expansion is driven by an increasing volume of complex, decentralized trials and a surging demand for temperature-sensitive biologics.
Pharmaceutical and biotechnology firms are increasingly moving away from fragmented service models in favor of integrated, end-to-end supply platforms. This shift is fueling strategic consolidation, exemplified by major acquisitions such as UPS’s $1.6 billion purchase of Andlauer Healthcare Group and DHL’s acquisition of CRYOPDP. These investments aim to bolster resilience in global supply chains, particularly for Phase III trials and oncology research, which demand stringent regulatory compliance and specialized handling of advanced therapies.
Comments (0)
No comments yet. Be the first!